First Time Loading...

Ultragenyx Pharmaceutical Inc
NASDAQ:RARE

Watchlist Manager
Ultragenyx Pharmaceutical Inc Logo
Ultragenyx Pharmaceutical Inc
NASDAQ:RARE
Watchlist
Price: 41.22 USD -0.82% Market Closed
Updated: May 10, 2024
Section:
 

Wall Street
Price Targets

RARE Price Targets Summary
Ultragenyx Pharmaceutical Inc

Wall Street analysts forecast RARE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RARE is 90.63 USD with a low forecast of 47.47 USD and a high forecast of 147 USD.

RARE Lowest Forecast
Wall Street Target
47.47 USD
15% Upside
RARE Average Forecast
Wall Street Target
90.63 USD
120% Upside
RARE Highest Forecast
Wall Street Target
147 USD
257% Upside
Lowest
Price Target
47.47 USD
15% Upside
Average
Price Target
90.63 USD
120% Upside
Highest
Price Target
147 USD
257% Upside

RARE Last Price Targets
Ultragenyx Pharmaceutical Inc

The latest public price target was made on Apr 15, 2024 by Dae Gon Ha from Stifel Nicolaus , who expects RARE stock to rise by 201% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Dae Gon Ha
Stifel Nicolaus
124 USD
Upside 201%
3 weeks ago
Apr 15, 2024
Stifel Reiterates Buy Rating on Ultragenyx Pharma (RARE)
StreetInsider
Christopher Raymond
Raymond James
130 USD
Upside 215%
3 weeks ago
Apr 15, 2024
Piper Sandler Reiterates Overweight Rating on Ultragenyx Pharma (RARE)
StreetInsider
Unknown Analyst
Morgan Stanley
95 USD
Upside 130%
1 year ago
Feb 3, 2023
Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $95
Benzinga
Dae Gon Ha
Stifel Nicolaus
Price Target 124 USD
Upside/Downside 201%
View Source
Christopher Raymond
Raymond James
Price Target 130 USD
Upside/Downside 215%
View Source
Unknown Analyst
Morgan Stanley
Price Target 95 USD
Upside/Downside 130%
View Source
Ultragenyx Pharmaceutical Inc Competitors:
Price Targets
3164
GenMont Biotech Inc
341% Upside
S
688180
Shanghai Junshi Biosciences Co Ltd
27% Upside
GTH
Genetron Holdings Ltd
67% Downside
2256
Abbisko Cayman Ltd
156% Upside
3164
GenMont Biotech Inc
341% Upside
S
688180
Shanghai Junshi Biosciences Co Ltd
27% Upside
GTH
Genetron Holdings Ltd
67% Downside
2256
Abbisko Cayman Ltd
156% Upside
OVID
Ovid Therapeutics Inc
157% Upside
PBYI
Puma Biotechnology Inc
8% Downside
1672
Ascletis Pharma Inc
117% Upside
GNS
Genus PLC
45% Upside

Revenue
Forecast

Revenue Estimate
Ultragenyx Pharmaceutical Inc

The compound annual growth rate of Ultragenyx Pharmaceutical Inc's revenue for the next 3 years is 27%.

N/A
Past Growth
27%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Ultragenyx Pharmaceutical Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Ultragenyx Pharmaceutical Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-41%
Average Miss
What are analyst estimates?

See Also

Summary
RARE intrinsic value, competitors valuation, and company profile.
DCF Valuation
RARE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RARE stock valuation using valuation multiples.
Wall Street Estimates
RARE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RARE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RARE's stock price target?
Price Target
90.63 USD

According to Wall Street analysts, the average 1-year price target for RARE is 90.63 USD with a low forecast of 47.47 USD and a high forecast of 147 USD.

What is Ultragenyx Pharmaceutical Inc's Revenue forecast?
Projected CAGR
27%

The compound annual growth rate of Ultragenyx Pharmaceutical Inc's revenue for the next 3 years is 27%.

ALPHA SPREAD
Join more than 135,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.